# Retatrutide Half-Life and Pharmacokinetics > Retatrutide half-life is approximately 6 days, supporting once-weekly dosing. Phase 1b pharmacokinetic data, albumin-binding design, and dose-PK relationships from published trials. How the Phase 1b trial established retatrutide's ~6-day half-life, what that means for weekly dosing, and the structural chemistry that produces it. ## The plain version Retatrutide half-life refers to how quickly the drug's concentration in the blood drops over time. A half-life of about 6 days means that 6 days after an injection, about half the amount in the bloodstream has been cleared. In 12 days, about three-quarters has cleared. This relatively slow clearance is what makes a once-weekly injection schedule work: each weekly shot maintains a fairly steady drug level between doses, without needing daily injections. The 6-day half-life was established in the Phase 1b first-in-human trial, published in The Lancet in 2022 [4]. It was not a coincidence — retatrutide was engineered specifically for this behavior by attaching a fatty-acid chain to the molecule that binds albumin (the most abundant protein in blood), which slows the body's clearance of the drug. This page documents the retatrutide half-life and pharmacokinetics (the full story of how the body absorbs, distributes, and clears the compound) from published trial data. ## The structural basis for extended half-life Retatrutide is a 39-amino-acid synthetic peptide with a molecular formula of C₂₂₁H₃₄₂N₄₆O₆₈ and a molecular weight of 4,731 Da. The extended half-life is a deliberate engineering feature: the molecule carries a C20 fatty-diacid acyl chain that binds reversibly to albumin in the bloodstream [3, 4]. Albumin binding is a well-established pharmacokinetic strategy for peptide-based drugs. Because albumin (the main protein carrier in blood plasma) is large and filtered poorly by the kidneys, anything attached to it is cleared much more slowly than a naked peptide would be. Retatrutide's albumin-binding design produces half-lives in the 5–7 day range compared to the sub-hour half-lives of the native GIP, GLP-1, and glucagon hormones it mimics. The cryo-EM structural study (Li W et al., Cell Discovery 2024) provided atomic-resolution confirmation of the triple-receptor binding mechanism [3], but the albumin-binding pharmacokinetics were separately characterized in the Phase 1b trial population. ## Phase 1b pharmacokinetic data The first-in-human Phase 1b trial (Urva S et al., Lancet 2022) enrolled 72 adults with type 2 diabetes (HbA1c 7.0–10.5%) and characterized retatrutide pharmacokinetics across dose cohorts of 0.5, 1.5, 3, 3→6, and 3→6→9→12 mg subcutaneously once weekly for 12 weeks [4]. Key pharmacokinetic findings: - **Half-life:** approximately 6 days — confirming that once-weekly administration is sufficient to maintain near-steady-state plasma concentrations - **Accumulation:** consistent with the half-life prediction, plasma concentrations rose appropriately over the first 3–4 weeks before reaching quasi-steady state - **Dose-proportionality:** plasma exposure (AUC) increased approximately proportionally with dose across the studied range - **Route:** subcutaneous injection only; intravenous and oral pharmacokinetics have not been published These PK characteristics are the direct pharmacological basis for the once-weekly clinical trial design in all subsequent Phase 2 and Phase 3 studies. ## Pharmacokinetic implications for dosing schedules The approximately 6-day half-life has two key practical consequences in trial design: **First, it supports once-weekly administration.** A 6-day half-life means roughly 85% of the previous week's dose is still circulating when the next injection is given. Drug levels do not fall dramatically between doses, which avoids the receptor cycling (repeated high-then-low stimulation) associated with daily or shorter-interval injections. **Second, it creates a slow approach to steady state.** With a 6-day half-life, it takes approximately 5–6 half-lives — or roughly 30–42 days — for plasma concentrations to reach steady state after starting a new dose or after a dose change. This is why Phase 2 trial dose-escalation schedules typically held each new dose level for 4–6 weeks before stepping up: to allow the new level to fully stabilize before assessing tolerability. These retatrutide half life dynamics are consistent across the Phase 1b, Phase 2, and Phase 3 populations, as the compound's albumin-binding pharmacokinetics are driven by structure rather than patient characteristics. Full [retatrutide results](/results) from the Phase 2 efficacy trials are summarized separately. ## Half-life context: comparison to related compounds For comparison: native GLP-1 has a half-life of 1–2 minutes in plasma before enzymatic degradation. The GLP-1 receptor agonists approved for clinical use have been engineered with varying half-life extensions — some use daily injection, some weekly. The 6-day half-life of retatrutide places it in the long-acting once-weekly subcutaneous class, consistent with the longer-acting approved dual-agonist in the same category. The glucagon and GIP native hormones have similarly very short half-lives of seconds to minutes. Retatrutide's albumin-binding design extends effective half-life across all three receptor arms simultaneously, since a single molecule carries all three pharmacophores. No oral or longer-acting depot formulation of retatrutide has been described in published literature. All trials used subcutaneous injection. --- A digest of the published trial record — not a clinic, not a formulary, and not a prescription.